(12/23, Sandle, De Sa'pinto) reports the European Medicines Agency
announced Thursday that it is reviewing medicines containing aliskiren
due to the ALTITUDE study, which showed that Novartis' Rasilez
[aliskiren] did not appear to benefit patients. In addition, patients
on aliskiren had more adverse effects including renal complications,
hyperkalemia, hypotension, and stroke. Also covering the story is Dow Jones Newswire (12/23, Baba, Subscription Publication).
No comments:
Post a Comment